Compare Amgen, Inc. (AMGN) vs International Business Machines Corp (IBM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs International Business Machines Corp — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while International Business Machines Corp trades at $288.81 (market cap $270.27B). The key difference: International Business Machines Corp is the larger of the two by market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | IBM | |
|---|---|---|
Market Cap | $196.12B | $270.27B |
Sector | Health | Technology |
52-Week High | $388.16 | $329.23 |
52-Week Low | $271.18 | $214.64 |
Enterprise Value | $241.41B | $328.29B |
Dividend Yield | 2.77% | 2.35% |
Volume | — | 4,481,527 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
IBM trades at $287.56, down 2.62% today, near key support at $288. The stock shows strong fundamentals with revenue growth to $67.54B in 2025 and net income margin of 15.61%. Recent quarterly earnings consistently beat estimates, and the technical outlook is bullish with moving averages signaling upward momentum. Analyst consensus price target is $309.07, suggesting potential upside from current levels.
Outlook remains positive driven by enterprise AI and quantum computing initiatives, though risks include competitive pressures in software and reliance on legacy systems. Wall Street sentiment is mixed with 47% buy ratings, but institutional interest remains strong. The upcoming Q2 2026 earnings report on July 22 will be critical for near-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About International Business Machines Corp
International Business Machines Corporation (IBM) provides computer solutions. The Company offers application, technology consulting and support, process design and operations, cloud, digital workplace, and network services, as well as business resiliency, strategy, and design solutions. IBM serves clients worldwide.
Read more on IBM →
